Peptide education
Epitalon
Epithalon · Epithalone · AEDG · Ala-Glu-Asp-Gly
Epitalon is a four-amino-acid peptide, Ala-Glu-Asp-Gly, that came out of a Russian research program on pineal gland extracts and aging. It has the best mechanism story in the longevity-peptide catalog: real papers showing melatonin rhythm changes in elderly volunteers and telomerase activation in human cells. It also has the catalog's characteristic gap: nobody has run a controlled trial showing anyone sleeps better, lives longer, or ages differently. Everything you have heard about it is two steps of extrapolation from a biomarker.
Epitalon's human evidence is biomarkers: melatonin rhythms and clock genes moved in small studies from one research lineage. Whether anyone sleeps better or lives longer was never measured, and the internet's 5 to 10 mg cycles run far above anything tested.
Overview
Quick answer
Epitalon is separate from Pinealon. Epitalon is AEDG and is usually discussed around pineal, melatonin, circadian, telomere, retina, and longevity claims. Pinealon is EDR and has different neurobiology and cognition evidence. Epithalamin is also not interchangeable with Epitalon; it is an adjacent pineal preparation, so older human melatonin papers need clear naming before they are applied to AEDG.
What is it?
A synthetic tetrapeptide, AEDG, developed from the epithalamin pineal-extract lineage and sold under the spellings Epithalon and Epithalone as well. It belongs to the Khavinson aging-research tradition, not to any approved medicine.
Why do people talk about it for sleep?
Because a few small studies found real circadian effects: higher evening and nighttime melatonin in older adults with reduced pineal function, and clock-gene shifts in night-shift workers. Those are biomarkers of sleep-timing biology. No Epitalon study has ever reported whether anyone actually slept better.
Why do people talk about it for longevity?
Because human cell studies reported telomerase activation and telomere-length findings, and telomeres are the public's favorite aging marker. Cell cultures cannot register lifespan, healthspan, or cancer risk, and no human longevity trial exists.
What study patterns are actually reported?
Tiny exposures by market standards: intramuscular 0.01 mg daily for 10 days in the elderly melatonin study, and a 0.5 mg per day sublingual spray for 20 days in the shift-worker gene study. Community cycles inject 5 to 10 mg daily on the assumption that the course format from the Russian gerontology literature transfers.
What is the bottom line?
A real circadian-biomarker signal and a real cell-mechanism story, both from a single research lineage, neither independently replicated in controlled trials. Interesting enough to watch; nowhere near enough to justify the longevity-peptide framing.
Reported practice
Commonly reported protocol
Community course-based protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Older human and primate studies link Epitalon/AEDG to melatonin rhythm, urinary 6-sulfatoxymelatonin, and circadian-gene expression. That supports a circadian hypothesis, not an established sleep therapy.
The sleep and circadian sources do not include Epitalon human trials reporting standard sleep endpoints such as actigraphy, polysomnography, sleep efficiency, awakenings, daytime sleepiness scales, or standard insomnia questionnaires.
Human cell-line and older somatic-cell work reports telomere or telomerase-pathway findings. They are relevant to mechanism, but they do not show whether Epitalon improves lifespan or healthspan.
Older pineal-preparation papers may provide relevant background, but Epithalamin findings need clear naming before they are applied to Epitalon/AEDG.
FDA compounding-risk materials name Epitalon in a setting where potential significant safety risks and missing safety information matter. That makes product identity, route, sterility, impurity, concentration, and labeling separate questions from the biology.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Epitalon improves sleep. | The human evidence is indirect. One older adult melatonin-rhythm study and a shift-work circadian-gene study are relevant to sleep timing biology, but they did not report standard sleep outcomes. | Melatonin rhythm, urinary melatonin metabolite output, cortisol rhythm, and clock genes can influence sleep timing and sleep propensity. That is why Epitalon shows up in sleep and circadian discussion. | Non-clinical discussion often describes vivid dreams, sleep disruption, timing experiments, or mixed sleep responses. They are useful anecdotes, not a sleep protocol, cycle, timing rule, or stack. | Reasonable as a circadian-biomarker hypothesis. Overstated when presented as a sleep-efficacy claim. |
| Epitalon is a longevity peptide. | No clinical longevity outcome trial shows longer lifespan, better healthspan, or fewer age-related events in people. | Reviews and cell studies discuss telomere length, telomerase activity, antioxidant effects, pineal signaling, and cellular-aging pathways. Those mechanisms explain the longevity interest, without showing a human longevity treatment effect. | Online and clinic-style discussions often compress "telomere mechanism" into anti-aging language. That leap leaves the hardest questions open: clinical endpoint, duration, population, safety, and product identity. | Useful for discussing the mechanism. Too thin for an anti-aging or lifespan-treatment claim. |
| Epitalon regulates circadian rhythm. | This is the strongest claim, with tight wording. Human and primate studies report melatonin-rhythm, urinary melatonin metabolite, and clock-gene changes after Epitalon/AEDG exposure. | The mechanism fits pineal and clock-gene biology: changes in melatonin signaling, cortisol rhythm, Cry2 expression, and Csnk1e expression are all relevant to circadian regulation. | Real-world reports use circadian language loosely, often without objective phase markers or sleep measures. | Reasonable as a biomarker-based circadian discussion. It is not the same thing as a treatment for a diagnosed circadian disorder. |
| Epitalon and Pinealon are one combined sleep stack. | The evidence separates the two compounds. Epitalon has the stronger circadian-biomarker support, while Pinealon has the EDR neuroprotection and cognition evidence. | Shared pineal or neurobiology language does not by itself justify combined use. Different peptide identities, targets, evidence, and safety questions need separate handling. | Non-clinical discussions may combine Pinealon and Epitalon, but the available evidence leaves stack and cycle language unverified and unsuitable for dosing or timing guidance. | Epitalon and Pinealon are different molecules with different claims. Combining the names does not make the stack a tested timing or dosing approach. |
| Epitalon is safe because some studies reported no side effects. | Some older papers describe no side effects in narrow study contexts, but the samples were small, follow-up was short, and adverse-event collection was not equivalent to a modern drug safety package. | Endocrine, circadian, immune, retinal, and telomere biology can matter differently across populations. Telomere-pathway claims also raise cancer-biology questions that cell papers cannot settle. | Product pages and forum discussions can make Epitalon sound routine, but they do not answer sterility, identity, endotoxin, impurity, dose accuracy, route-specific safety, or batch consistency. | Safety confidence is low, especially for compounded or research-market injectable products. |
Bottom line
Main takeaway
Epitalon is a four-amino-acid peptide with a genuine mechanism story and no outcome trials. Melatonin rhythms moved in small studies; sleep quality and lifespan were never measured.
Watch for two conversions: circadian biomarkers sold as sleep outcomes, and telomerase in cell cultures sold as longevity in people. Most Epitalon marketing is one of those two swaps.
The base is one lineage: the elderly melatonin-rhythm study, the shift-worker clock-gene study, the telomere cell papers, and the AEDG review, plus an empty trial registry. Independent replication is the missing ingredient.
Identity
What it is
Epitalon is the tetrapeptide Ala-Glu-Asp-Gly, AEDG, also spelled Epithalon or Epithalone. It descends from epithalamin, a pineal-gland extract studied in Russian gerontology, and it carries that field's central idea: the pineal drives aging, so a pineal peptide might slow it.
The human data is circadian, not clinical. In older adults with reduced pineal function, 10 days of small intramuscular doses raised evening and nighttime melatonin. In night-shift workers, a 20-day sublingual course shifted clock-gene expression, and aged monkeys showed melatonin and cortisol rhythm changes. Real measurements, all biomarkers, none asking whether sleep or health improved.
The longevity wing rests on cells: telomerase activation and telomere-length findings in human cell cultures. Telomere biology is a legitimate research topic and a weak basis for a consumer claim, since cell cultures cannot register lifespan, healthspan, or cancer risk.
One separation matters here: Epitalon is not Pinealon, the EDR tripeptide, and not epithalamin, the parent extract. Marketing blends the three; each has its own evidence, or lack of it.
How people talk about it online
Longevity communities run Epitalon in courses: commonly 5 to 10 mg injected daily for 10 to 20 days, repeated once or twice a year, a format borrowed from the Russian gerontology literature. Sleep communities report vivid dreams, timing experiments, and mixed results, often in stacks with Pinealon.
Two overstatements do most of the work online: turning cell telomere findings into a human anti-aging claim, and turning melatonin-rhythm biomarkers into a sleep therapy. Nearly every Epitalon sales page makes at least one of those moves.
The dose gap deserves attention. The studied human exposures were 0.01 mg and 0.5 mg per day; community cycles inject 5 to 10 mg, anywhere from ten to a thousand times that depending on the comparison. Nobody has bridged the two, so the popular schedules rest on the course format, not on any measured dose-response.
Use context
Routes, doses, and cycle patterns
Epitalon use descriptions split into two groups. The more reliable group comes from small circadian or endocrine studies with specific routes, amounts, and short durations. The real-world group is non-clinical discussion: cycles, stacks, vivid dreams, sleep disruption, and longevity routines without clinical-outcome support.
Human studies and product labels
Older-adult melatonin rhythm study
- Purpose
- Circadian melatonin rhythm in older adults with reduced pineal function
- Context
- Small controlled human biomarker study
- Route
- Intramuscular
- Amount
- 0.01 mg per day; 0.1 mg total course reported in the review summary
- Frequency
- Once daily, administered in the morning in the study report
- Duration
- 10 injections over 10 days
The measured outcome was plasma melatonin at circadian sampling times, including 21:00 and 03:00. This is relevant to circadian signaling, but it is not a direct sleep outcome.
Night-shift worker clock-gene study
- Purpose
- Circadian gene expression under shift-work stress
- Context
- Human biomarker and gene-expression study
- Route
- Sublingual spray
- Amount
- 0.5 mg AEDG per day reported in the review summary
- Frequency
- Twice daily, morning and early afternoon, in the review summary
- Duration
- 20 days
Cry2 expression increased and Csnk1e expression decreased in the review summary. Those are molecular circadian markers, not sleep efficiency, sleep onset, awakenings, or daytime sleepiness outcomes.
Senescent monkey endocrine rhythm study
- Purpose
- Melatonin and cortisol rhythmicity in aged animals
- Context
- Non-human primate endocrine study
- Route
- Intramuscular
- Amount
- 10 micrograms per animal in the review summary
- Frequency
- Once daily in the morning
- Duration
- 10 days
The study matters for mechanism because it connects Epitalon to evening melatonin and cortisol rhythm in old animals. It is not human sleep benefit evidence.
Real-world discussion
Community course-based protocols
- Purpose
- Longevity and telomere-adjacent discussion
- Context
- Clinics, forums, and vendor listings
- Route
- Subcutaneous injection
- Amount
- Commonly around 5 to 10 mg per day for 10 to 20 consecutive days, following the course patterns in the Russian gerontology literature.
- Frequency
- Once daily during a course
- Duration
- 10 to 20 day courses, commonly repeated once or twice per year
The course-based pattern comes from the Khavinson-lineage literature rather than controlled trials; community schedules imitate it directly. Reported as context, not a recommendation.
What varies
- Goal: a circadian biomarker question is different from a sleep-quality, insomnia, or longevity outcome question.
- Route: intramuscular and sublingual study patterns do not automatically match oral capsules, research vials, sprays, or compounded products.
- Amount: the cited human biomarker studies used very small amounts compared with many online peptide discussions, so cross-source comparisons are fragile.
- Timing: morning administration appears in the circadian studies, but that is study context, not a general timing rule.
- Cycle: online cycle language exists, but the cited studies do not give a repeat-cycle protocol.
Human data
Human evidence
Epitalon has human biomarker evidence and no human outcome evidence. The two relevant studies, melatonin rhythm in elderly volunteers and clock-gene expression in night-shift workers, measured circadian signals rather than sleep, and both come from the same research lineage. Both also ran in older or rhythm-disrupted subjects: where melatonin production is already intact, the reported effect largely disappears. The telomere findings are human cell cultures, not people. The trial registry holds no Epitalon sleep, longevity, or circadian-disorder trial, and FDA compounding materials flag missing safety information, which is where the record currently ends.
Evidence maturity
Epitalon's evidence is a single research lineage's in-vitro and small human work: decades of marketing, no controlled trials.
Telomerase activation reported in human somatic cell cultures.
Melatonin-rhythm and aging-population reports from the Khavinson lineage.
None meeting modern standards.
Longevity clinics, plus the July 24, 2026 PCAC vote recommending Epitalon bulk substances for the 503A Bulks List (7-5, one abstention). The recommendation is non-binding; FDA rulemaking follows, so compounding status is unchanged today.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Older adults with reduced pineal function | Healthy elderly people, with subgroup interpretation around reduced pineal melatonin production | Small controlled human biomarker study | Epitalon/AEDG study material; not a commercial product validation | Plasma melatonin increased at evening and nighttime sampling points in the review summary, including 21:00 and 03:00 measures. | The endpoint was melatonin rhythm, not sleep. The sample was small, the literature is older, and the result is not a clinical insomnia-treatment or longevity result. | Limited human biomarker evidence |
| Shift-work circadian gene-expression study | Middle-aged women working night shifts, with reduced melatonin-function subgrouping in the review summary | Human biomarker and gene-expression study | Sublingual AEDG study exposure; not a broad product-quality claim | The summary reported Cry2 expression increased and Csnk1e expression decreased after AEDG exposure. | Peripheral clock-gene expression is not a sleep endpoint, so it does not answer sleep duration, sleep efficiency, alertness, or long-term safety. | Limited human biomarker evidence |
| Epitalon telomere and telomerase cell literature | Human cell lines and somatic-cell models | Cell and mechanism studies plus review context | Laboratory mechanism work | Sources report telomere-length or telomerase-pathway findings relevant to the longevity claims. | Cell findings leave human healthspan, lifespan, cancer risk, clinical benefit, dose selection, and real-world safety unanswered. | Mechanistic and preclinical |
| ClinicalTrials.gov Epitalon search | Registry-search context | Registry search | Registry search did not find matching Epitalon trial records | The registry check did not find a human sleep, longevity, or circadian-disorder trial. | A registry search cannot rule out every possible study. It is a current trial-registry check for Epitalon. | Registry context |
Use context
Reported use context
Reported Epitalon use patterns fall into two groups. The published examples are short biomarker studies. Online cycles, stacks, vivid-dream reports, and longevity routines explain the public interest, but they do not establish an amount, schedule, or repeat-cycle pattern.
Study and label context
0.01 mg daily for 10 days, 0.1 mg total course, in the review summary. This is biomarker-study exposure, not sleep or longevity use guidance.
0.5 mg per day for 20 days, described as twice daily in the review summary. This is gene-expression study exposure, not a sleep-use routine.
Real-world discussion
Online cycles and routines are part of the public conversation, especially around longevity and telomeres. Community descriptions commonly converge on course-based use of roughly 5 to 10 mg per day for 10 to 20 consecutive days, repeated once or twice per year, following the Russian gerontology literature. This is background to the claim; telomere mechanism papers cannot show whether real-world routines change sleep, aging, or safety outcomes.
Reports mention vivid dreams, sleep disruption, circadian reset language, and stack attribution problems. This is unverified discussion; no sleep endpoint or use pattern is attached.
Cautions
Safety and unknowns
- Direct adverse-event reporting is weak. Small studies and review statements about no side effects do not equal a modern long-term safety package.
- Route-specific safety depends on route and product. Intramuscular study exposure, sublingual study exposure, oral products, compounded products, and research-market vials are not directly comparable.
- Telomere and telomerase biology creates a special interpretation problem: cell findings matter, while cancer-biology relevance and long-term clinical risk need a different evidence base.
- Circadian effects could plausibly shift sleep timing, daytime alertness, mood, or endocrine rhythms. The current sources do not define who is likely to benefit or be harmed.
- FDA compounding-risk materials leave the practical safety questions unresolved: product identity, route, impurities, aggregation, sterility, endotoxin, dose accuracy, and missing human safety information.
Product quality
A vial label is only a starting point
A product labeled Epitalon does not become reliable just because AEDG has a PubMed mechanism literature. Identity, purity, sterility, endotoxin, potency, stability, container, storage, and chain of custody still have to be checked for the actual product.
Gray-market or compounded products can borrow the language of melatonin, telomeres, and longevity without showing that the vial, spray, capsule, or lot matches the studied material.
Identity
The label needs to match AEDG/Epitalon rather than a related pineal preparation, wrong peptide, blend, or mislabeled product.
Route-specific quality
Injection, sublingual, and oral exposure have different sterility, formulation, stability, and absorption questions.
Batch evidence
A general purity claim leaves representative lot testing, endotoxin control, sterile handling, concentration accuracy, and shipping stability undocumented.
Claim separation
Telomere and circadian papers cannot show that a marketed product is effective, safe, authentic, or suitable for human use.
Mechanism
How it is proposed to work
Epitalon is a pineal and cellular-aging mechanism topic. AEDG has been linked to melatonin rhythm, circadian gene expression, antioxidant and neuroendocrine themes, and telomere or telomerase pathways. Those mechanisms can explain interest in sleep and longevity, but they do not replace clinical outcome trials.
Melatonin rhythm findings matter because melatonin is a core darkness signal. A stronger or more normally timed melatonin signal could plausibly affect sleep timing, but the current Epitalon studies measured biomarkers rather than sleep itself.
Circadian gene findings such as Cry2 and Csnk1e movement are molecular signals in peripheral cells. They are mechanistic clues and do not by themselves show better sleep architecture or shift-work adaptation.
Telomerase and telomere-length findings in human cell lines are central to longevity claims. They remain laboratory findings unless tied to clinical endpoints and safety data.
Epithalamin-adjacent literature can inform the pineal-preparation history, but it needs explicit naming separation from Epitalon/AEDG.
FAQ
Common questions
Is Epitalon use guidance included?
Study regimens can be summarized as research conditions, but they do not establish dose, timing, source, or combination rules.
Do telomere findings prove Epitalon is a longevity treatment?
No. The current telomere source is a cell-line study, so it informs mechanism discussion rather than clinical longevity conclusions.
Details
Technical details
Sources
References
- 1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 3.
PubMed. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties 2025.
doi:10.3390/ijms26062691 PMID:40141333 Accessed 2026-06-08.
Review article for Epitalon/AEDG mechanism and translational context; claims still require evidence-type separation.
- 4.
PubMed. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity 2025.
doi:10.1007/s10522-025-10315-x PMID:40908429 Accessed 2026-06-08.
Human cell-line study reporting telomere-pathway effects; not a clinical longevity outcome study.
- 5.
PubMed. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells 2003.
PMID:12937682 Accessed 2026-06-08.
Human somatic cell source for telomerase/telomere mechanism; not a clinical longevity outcome.
- 6.
PubMed. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging 2020.
PMID:33280326 Accessed 2026-06-09.
Russian-language human biomarker/gene-expression source for AEDG and circadian-gene context; not a sleep efficacy or protocol source.
- 7.
PubMed. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people 2007.
PMID:17969590 Accessed 2026-06-09.
Older human and non-human primate melatonin-rhythm source naming Epitalon/AEDG; biomarker context, not sleep efficacy or use guidance.
- 8.
PubMed. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people 2004.
PMID:15452611 Accessed 2026-06-08.
Epithalamin adjacent source; not the same as Epitalon/AEDG.
- 9.
PubMed. Peptides of pineal gland and thymus prolong human life 2003.
PMID:14523363 Accessed 2026-06-08.
Epithalamin-adjacent source requiring careful naming separation.
- 10.
ClinicalTrials.gov. ClinicalTrials.gov search for Epitalon 2026.
Accessed 2026-06-08.
No matching Epitalon clinical trial records were used from the current registry search.
- 11.
PubMed. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes 2024.
doi:10.3390/ijms252111363 PMID:39518916 Accessed 2026-06-08.
In vitro induced-neuron study including EDR and AEDG; supports mechanism discussion but not clinical sleep or longevity claims.